Web Exclusives

Cancer affects all races, ethnicities, sexual orientations, genders, and nationalities. Read More ›

Cervical cancer during pregnancy can be successfully managed with a multidisciplinary treatment team and an individualized treatment strategy that optimizes maternal treatment while considering fetal safety. Read More ›

On November 22, 2021, the FDA approved Fyarro (sirolimus protein-bound particles for injectable suspension (albumin-bound); from Aadi Bioscience) for adults with locally advanced, unresectable or metastatic malignant perivascular epithelioid-cell tumor (PEComa), a rare type of mesenchymal tumors that can occur in any part of the body.

Read More ›

On August 17, 2021, the FDA accelerated the approval of Jemperli (dostarlimab-gxly; from GlaxoSmithKline) injection, an immunotherapy and a PD-1 inhibitor, for the treatment of all adults with recurrent (coming back) or advanced mismatch repair-deficient (dMMR) solid tumors, including lung cancer, that progressed during or after systemic therapy and for whom there are no satisfactory alternative treatment options. Read More ›

Although we are entering another winter with the ongoing prevalence of the coronavirus, we have come a long way since the initial outbreak. Here are some reasons for patients to be optimistic for the season. Read More ›

The combination of acalabrutinib, venetoclax, and obinutuzumab has been shown to be an active regimen in previously untreated patients with CLL. Read More ›

During the first 13 months of the pandemic, COVID-19 continued to result in high hospitalization rates among patients with CLL. Read More ›

Identifying the risk factors for infection may allow preventive measures to be taken to protect patients. Read More ›

Oral targeted therapies have revolutionized treatment for patients with CLL but ensuring that they are taken as prescribed is crucial to achieving optimal outcomes. Read More ›

Copay assistance coupons and copay adjustment programs put patients in the middle of healthcare cost-saving measures. Read More ›